METTL3 inhibitor suppresses the progression of prostate cancer via IGFBP3/AKT pathway and synergizes with PARP inhibitor
Article in Biomedicine & Pharmacotherapy (September 2024)
The most recent citing publications are shown below. View all 11 publications that cite this research output on Dimensions.
Article in Biomedicine & Pharmacotherapy (September 2024)
Article in Frontiers in Pharmacology (August 2024)
Article in Neoplasia (July 2024)